Xilio Therapeutics, Inc. (XLO) Stock

Xilio Therapeutics, Inc. (XLO) is a Healthcare stock trading at $9.11 (as of 2026-08-21), with a market capitalization of $52.68M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapy candidates aimed at strengthening anti-tumor immune responses in cancer patients. Its pipeline includes a tumor-selective anti-CTLA-4 monoclonal antibody program and cytokine-based assets (IL-2, IL-12, and IL-15) designed to remain masked until activation in the tumor microenvironment.

Understand Xilio Therapeutics, Inc.: how it makes money

Xilio Therapeutics develops immunotherapies for cancer patients, including checkpoint inhibitor (XTX101) and cytokine programs (XTX202, XTX301, XTX401). It makes money mainly through collaborations and licensing, while its clinical-stage programs drive ongoing development and research spending.

For a clinical-stage biotech, the profit model depends on whether early clinical signals (for programs like XTX101) can attract or renew collaboration and license funding, because product revenue is not shown as a meaningful driver in the provided data.

Revenue by segment (latest quarter)
Collab$0.0B
License$0.0B

Business quality (Weak): Clear pipeline and trial metrics, but limited reported revenue detail (revenue near zero in the provided quarter) makes financial trend interpretation harder.

Bull case

  • Clinical activity to monitor: The company reports an Objective Response Rate of 40.0% and provides trial-related context such as Anticipated Phase 2 Patient Enrollment of 40.
  • Revenue linked to external validation: Collaboration and License Revenue is present (0.01 USD_B), which can reflect continued external interest as programs advance.

Bear case

  • Early-stage biology and outcomes uncertainty: The programs are in early clinical development (XTX101 in Phase 1/2), so efficacy signals like Objective Response Rate may not persist or scale in later studies.
  • Treatment tolerability risk: The company reports Treatment Discontinuations Due to Treatment-Related Adverse Events at 5.0% and Colitis Incidence (Patients Reporting Colitis) at 7.0%, which could affect future dosing and trial results.
Valuation — source: SEC EDGAR (first-party)
Price$9.11
Market Cap$52.68M
Price / Book0.73
Price / Sales0.82
FCF Yield-116.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$43.77M
Net Margin-80.1%
Revenue Growth (YoY)131.2%
EPS Growth (YoY)106.3%
FCF Growth (YoY)26.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.45 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGILEAD SCIENCES, INC. ($5.47M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORene Russo
Employees64
CountryUS
IPO Date2021-10-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • RenovoRx, Inc. (RNXT)
  • Stablecoin Development Corp (SDEV)
  • Clene Inc. (CLNN)
  • Context Therapeutics Inc. (CNTX)
  • Impact BioMedical Inc. (IBO)
  • TransCode Therapeutics, Inc. (RNAZ)
  • Hyperion DeFi, Inc. (HYPD)
  • Tenax Therapeutics, Inc. (TENX)
XLO earnings history · XLO institutional & insider holders · XLO KPIs & operating metrics · XLO financials · XLO investor presentations & press releases · XLO SEC filings · XLO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.